Key facts
- Liom’s last known valuation is $63.0M (Apr 2021).
- It has raised $27.2M; the latest was Later Stage VC ($2.2M) in Dec 2025.
- Notable investors include b2venture, Alejo Ribalta, Daniel Gutenberg, Edward Ludwig, GE HealthCare Technologies — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Liom
- ·The full record, as it builds
Funding rounds
No funding rounds for Liom are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Liom
Developer of medical products designed to improve the well-being of human life. The company's product uses detection techniques to monitor vital medical indicators and benchmark platforms for longevity and preventative medicine by providing real-time biomarker and drug analysis to empower clinicians, enabling healthcare professionals to provide patients with a safe and healthy life.
- Sector
- Healthcare
- HQ
- Pfaffikon, Switzerland
- Founded
- 2017
- Employees
- 72
- Website
- liom.com/
- Ownership
- Privately Held (backing)
Liom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Liom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Liom in its N-PORT filings yet. We sweep new filings monthly.